23:43 , May 31, 2018 |  BC Innovations  |  Emerging Company Profile

Oral route for HAE

The team behind Firazyr icatibant has reunited to develop an oral version of the drug that could give hereditary angioedema patients the alternative to injectables they’ve been asking for. Pharvaris B.V. brings together team members responsible...
15:27 , May 25, 2018 |  BC Week In Review  |  Company News

Takeda divests stake in Chinese JV Techpool

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) spokesperson Vince Docherty told BioCentury on May 23 that the pharma's divestment of critical care and API manufacturing JV Guangdong Techpool Bio-Pharma Co. Ltd. (Guangzhou, China) does not signal a...
22:34 , May 23, 2018 |  BC Extra  |  Company News

Takeda divests stake in Chinese JV

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) spokesperson Vince Docherty told BioCentury on Wednesday that the pharma's divestment of critical care and API manufacturing JV Guangdong Techpool Bio-Pharma Co. Ltd. (Guangzhou, China) does not signal a strategic...
22:55 , May 11, 2018 |  BioCentury  |  Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May 8,...
21:10 , Apr 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Diabetic macular edema (DME) In vitro, mouse and rat studies identified two bicyclic peptide inhibitors of KLKB1 that could help treat DME. Screening of a bicyclic peptide library in KLKB1 binding assays followed by optimization...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global biopharma...
21:02 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Priority review for Shire's HAE prophylactic

FDA accepted and granted Priority Review to a BLA for lanadelumab (SHP643) from Shire plc (LSE:SHP; NASDAQ:SHPG) to prevent hereditary angioedema (HAE) attacks in patients ages 12 and older. Its PDUFA date is Aug. 26. The...
22:09 , Feb 23, 2018 |  BC Extra  |  Company News

Priority Review for Shire's HAE prophylactic

FDA accepted and granted Priority Review to a BLA for lanadelumab (SHP643) from Shire plc (LSE:SHP; NASDAQ:SHPG) to prevent hereditary angioedema (HAE) attacks in patients ages 12 and older. Its PDUFA date is Aug. 26. The...
02:03 , Jan 27, 2018 |  BioCentury  |  Finance

All together now

Promising proof-of-concept data from BioCryst Pharmaceuticals Inc. and a management team from Idera Pharmaceuticals Inc. with the requisite market know-how proved the right combination for a merger of two of the industry’s longest-standing independent small...
16:46 , Jan 26, 2018 |  BC Week In Review  |  Company News

BioCryst, Idera merging

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said Jan. 22 it will merge with Idera Pharmaceuticals Inc. (NASDAQ:IDRA) to form a company focused on rare diseases. The combined company will be renamed when the merger closes, which is...